Tove Wästerlid (Former)
1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
The National Swedish Lymphoma Register – a systematic validation of data quality
(
- Contribution to journal › Article
- 2022
-
Mark
Application of precision medicine in clinical routine in haematology—Challenges and opportunities
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients
(
- Contribution to journal › Article
- 2019
-
Mark
Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma : a Swedish lymphoma register study
(
- Contribution to journal › Article
- 2017
-
Mark
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
(
- Contribution to journal › Letter
- 2016
-
Mark
Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms
2016)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Högintensiv cytostatikaterapi ökade överlevnad vid burkitts lymfom
(
- Contribution to journal › Article
- 2015
-
Mark
Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.
2015) In Hematological Oncology(
- Contribution to journal › Article
- 2013
-
Mark
Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.
(
- Contribution to journal › Article